Hancock Whitney’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Hancock Whitney’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,433	Closed	-$227K	–	861
2021 Q1	$227K	Buy	+5,433	New	+$252K	0.01%	713
2020 Q4	–	Sell	-5,515	Closed	-$234K	–	856
2020 Q3	$234K	Buy	5,515 +209	+4%	+$9.14K	0.01%	684
2020 Q2	$255K	Sell	5,306 -2,130	-29%	-$106K	0.01%	659
2020 Q1	$342K	Sell	7,436 -4,620	-38%	-$232K	0.01%	598
2019 Q4	$724K	Buy	12,056 +2,976	+33%	+$177K	0.02%	502
2019 Q3	$514K	Sell	9,080 -601	-6%	-$33.8K	0.02%	585
2019 Q2	$539K	Buy	+9,681	New	+$505K	0.02%	605

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Hancock Whitney's EGRX Position: Q2 2021 in Review

Hancock Whitney sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 5,433 shares — an estimated $227K sold.

Hancock Whitney first reported a position in EGRX in Q2 2019 and held it in 7 quarters. The position peaked at $724K in Q4 2019. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

Hancock Whitney reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Hancock Whitney sold 5,433 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $227K.
Hancock Whitney first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2019 and held it in 7 quarters.
Hancock Whitney's Eagle Pharmaceuticals, Inc. position peaked at $724K in Q4 2019.
146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Hancock Whitney's 13F filing for Q2 2021, filed 9 Aug 2021.